Beijing-based China Medical Technologies said this week that China's State Food and Drug Administration has approved its real-time PCR-based KRAS assay as a companion diagnostic test for the use of a targeted colorectal cancer drug.

KRAS mutations occur in 30 percent to 60 percent of colorectal cancers and are associated with poor response to EGFR inhibitors such as Amgen's Vectibix and Merck's Erbitux.

China Medical did not disclose the name of the drug for which its assay was approved as a companion diagnostic.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.